[Drug-eluting or bare-metal stents in interventional cardiology. Theory and practice].
Drug-eluting stents (DES) reduce the restenosis rate after coronary interventions. They became the third milestone of interventional cardiology after coronary angioplasty and stent implantation. However, studies with hard endpoints showing a beneficial effect of DES are still missing. Recent metaanalyses are even suggesting a higher mortality in patients with DES. Now, before DES become avoided, exact indications and limitations have to be defined.
Er
Fikret
F
Medizinische Klinik III, Universität zu Köln, Kerpener Strasse 62, 50937 Köln.
Erdmann
Erland
E
D015906:Angioplasty, Balloon, Coronary; D002986:Clinical Trials as Topic; D020099:Coated Materials, Biocompatible; D023903:Coronary Restenosis / Q000401:mortality / Q000517:prevention & control*; D016503:Drug Delivery Systems; D006801:Humans; D015201:Meta-Analysis as Topic; D017239:Paclitaxel / Q000008:administration & dosage* / Q000009:adverse effects; D020123:Sirolimus / Q000008:administration & dosage* / Q000009:adverse effects; D015607:Stents; D015996:Survival Rate
D020099:Coated Materials, Biocompatible; D017239:Paclitaxel; D020123:Sirolimus